The effect of neprilysin (LCZ696) on exercise tolerance, muscle vasodilatation, muscle strength and body composition in patients with heart failure - NEPRIExTol-HF trial

• Grant number: 16/24833-0
• Support Opportunities: Regular Research Grants
• Start date: September 01, 2017
• End date: August 31, 2019
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Antonio Carlos Pereira-Barretto
• Grantee: Antonio Carlos Pereira-Barretto
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Marcelo Rodrigues dos Santos

Abstract

Heart failure (HF) with reduced ventricular ejection fraction is a disease that affects around 5.7 million people in the United States, with a mortality rate of approximately 50% within 5 years. HF is characterized by an exacerbation of the renin-angiotensin-aldosterone system (RAAS), which leads to an increase in sympathetic nerve outflow, peripheral vasoconstriction, and reduced functional capacity. Moreover, many clinical trials have been developed for the treatment of HF patients focused on inhibition of RAAS, such as enalapril. Nevertheless, hospitalization and mortality rates in this population are excessive. However, studies with new drugs, such as the combination of valsartan/sacubitril, also known as LCZ696, have demonstrated important clinical impact on the morbidity and mortality outcomes in HF population. However, the effect of LCZ696 on the pathophysiological mechanisms of HF such as exercise tolerance (peak VO2) and peripheral muscle blood flow is not known. Since LCZ696 is a new drug with promising effects on the treatment of HF, the objective of the present study will be to evaluate the effect of LCZ696 in patients with HF on: 1) peak VO2, 2) 6-minute walk test, 3) peripheral muscle blood flow, 4) muscle strength, and 5) body composition. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DOS SANTOS, MARCELO RODRIGUES; PEIXOTO DA FONSECA, GUILHERME WESLEY; SHERVENINAS, LETICIA PIRONATO; DE SOUZA, FRANCIS RIBEIRO; BATTAGLIA FILHO, ANTONIO CARLOS; NOVAES, CAIO EDUARDO; RODRIGUES PEREIRA, ROSA MARIA; NEGRAO, CARLOS EDUARDO; PEREIRA BARRETTO, ANTONIO CARLOS; DE NAZARE NUNES ALVES, MARIA-JANIEIRE. Android to gynoid fat ratio and its association with functional capacity in male patients with heart failure. ESC HEART FAILURE, v. 7, n. 3, MAR 2020. (15/22814-5, 16/24833-0, 16/24306-0)

DOS SANTOS, MARCELO RODRIGUES; NUNES ALVES, MARIA-JANIEIRE DE NAZARE; JORDAO, CAMILA PAIXAO; NOVAES PINTO, CAIO EDUARDO; SOUZA CORREA, KELLY THAYANE; DE SOUZA, FRANCIS RIBEIRO; PEIXOTO DA FONSECA, GUILHERME WESLEY; TOMAZ FILHO, JOAQUIM; COSTA, MARCEL; RODRIGUES PEREIRA, ROSA MARIA; et al. Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study. AMERICAN HEART JOURNAL, v. 239, p. 1-10, SEP 2021. (16/24833-0, 16/24306-0, 19/14938-7)

DOS SANTOS, M. R.; FONSECA, G. W. P.; SHERVENINAS, L.; SOUZA, F. R.; BATTAGLIA FILHO, A. C.; PEREIRA, R. M. R.; NEGRAO, C. E.; ALVES, M. J. N. N.; BARRETTO, A. C. P.. Android to gynoid fat ratio and its association with functional capacity in male patients with heart failure. EUROPEAN HEART JOURNAL, v. 40, p. 1-pg., 2019-10-01. (16/24306-0, 16/24833-0)